Quick Answer
Relay Therapeutics, Inc. reported Stockholders Equity of $567.06 million for fiscal year 2025.
Relay Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $567.06M | -27.1% |
| 2024 | $777.79M | +3.4% |
| 2023 | $752.00M | -20.9% |
| 2022 | $950.22M | +5.8% |
| 2021 | $897.81M | +17.6% |
| 2020 | $763.29M | +523.0% |
| 2019 | -$180.44M | -62.7% |
| 2018 | -$110.93M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $607.71M | -27.6% | -8.7% |
| June 30, 2025 | $665.66M | -2.4% | -7.7% |
| March 31, 2025 | $721.08M | -3.3% | -7.3% |
| December 31, 2024 | $777.79M | +3.4% | -7.3% |
| September 30, 2024 | $838.86M | +7.8% | +23.0% |
| June 30, 2024 | $681.74M | -15.8% | -8.6% |
| March 31, 2024 | $745.76M | -15.6% | -0.8% |
| December 31, 2023 | $752.00M | -20.9% | -3.4% |
- Relay Therapeutics, Inc. showed a decrease of -27.1% in Stockholders Equity compared to the prior fiscal year.
- Over the 2018–2025 period, Relay Therapeutics, Inc.’s stockholders equity has grown by 611.2% (from -$110.93 million to $567.06 million).
- The most recent figure is from Relay Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: